tiprankstipranks

Zymeworks price target raised to $16 from $15 at Guggenheim

Guggenheim analyst Charles Zhu raised the firm’s price target on Zymeworks to $16 from $15 and keeps a Buy rating on the shares. The analyst said that full ASCO GI data continues to look "great," even prior to layering on PD-1. Zhu noted that, if he had to nitpick, the headline mDOR for zani + CAPOX was 10.4 months.

Confident Investing Starts Here:

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on ZYME:

Disclaimer & DisclosureReport an Issue